Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Newer antibiotic more effective at treating elders’ pneumonia

25.01.2006


A newer antibiotic medication proved more effective at knocking out community-acquired pneumonia (CAP) in patients 65 and older than the antibiotic that has been the front-line CAP treatment the last decade, according to a national study coordinated at The University of Texas Health Science Center at San Antonio.



CAP is the fifth-leading cause of death in the elderly, is diagnosed in 5.6 million adults annually in the U.S., and is 60 percent more likely to occur in the elderly than in the general population. The Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE) study, led by Antonio Anzueto, M.D., professor of medicine at the Health Science Center, is reported in the current issue of Clinical Infectious Diseases.

"The CAPRIE study is very unique in that it was conducted only in patients 65 and older, such as the median age was 78," Dr. Anzueto said. "Community-acquired pneumonia is a common infectious disease process in the elderly. Pneumonia has been identified as the leading infectious disease associated with the higher mortality (death) in this age group. This is also the first time the two leading antibiotics for CAP have been compared in a well-controlled clinical trial."


Treated with the newer medication, moxifloxacin HCI, 97.9 percent of hospitalized patients recovered within three to five days of therapy onset, compared to 90 percent of patients treated with the standard medication, levofloxacin. Study findings were in 281 patients at 47 centers.

"At the end of the day, another important question was safety," Dr. Anzueto said. "This study involved very sophisticated assessment of cardiac safety. We found both treatments to be safe." San Antonio patients were treated at the South Texas Veterans Health Care System.

Moxifloxacin HCI’s greater efficacy earlier in hospital stays should lead to less occurrence of incapacitating long-term effects, Dr. Anzueto said.

Moxifloxacin HCI and levofloxacin are in a group of antibiotics known as fluoroquinolones.

Will Sansom | EurekAlert!
Further information:
http://www.uthscsa.edu

More articles from Studies and Analyses:

nachricht The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung

nachricht A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>